680 related articles for article (PubMed ID: 9458712)
41. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
[TBL] [Abstract][Full Text] [Related]
42. The role of Ca2+ in regulating the catabolism of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in rabbit platelets.
Touqui L; Shaw AM; Dumarey C; Jacquemin C; Vargaftig BB
Biochem J; 1987 Jan; 241(2):555-60. PubMed ID: 3109377
[TBL] [Abstract][Full Text] [Related]
43. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
44. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
45. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
[TBL] [Abstract][Full Text] [Related]
46. Competitive inhibition of tritium-labeled platelet-activating factor binding to rabbit platelet membranes by amiloride and amiloride analogs.
Hwang SB
Biochem Biophys Res Commun; 1989 Aug; 163(1):165-71. PubMed ID: 2549986
[TBL] [Abstract][Full Text] [Related]
47. Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.
Kloprogge E; Akkerman JW
Biochem J; 1984 Nov; 223(3):901-9. PubMed ID: 6150705
[TBL] [Abstract][Full Text] [Related]
48. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
49. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Cailleau C; Maffrand JP
J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
[TBL] [Abstract][Full Text] [Related]
50. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
51. Rabbit blastocysts accumulate platelet-activating factor (PAF) and lyso-PAF in vitro.
Jones MA; Kudolo GB; Harper MJ
Mol Reprod Dev; 1992 Jul; 32(3):243-50. PubMed ID: 1323306
[TBL] [Abstract][Full Text] [Related]
52. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
Weber KH; Heuer H
Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
[TBL] [Abstract][Full Text] [Related]
53. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
[TBL] [Abstract][Full Text] [Related]
54. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists.
Tokumura A; Yoshida J; Okasaka N; Fukuzawa K; Tsukatani H
Thromb Res; 1987 Apr; 46(1):153-61. PubMed ID: 3590110
[TBL] [Abstract][Full Text] [Related]
55. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation.
Svetlov SI; Howard KM; Miwa M; Flickinger BD; Olson MS
Arch Biochem Biophys; 1996 Mar; 327(1):113-22. PubMed ID: 8615681
[TBL] [Abstract][Full Text] [Related]
56. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
57. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
58. Effect of the PAF-receptor antagonist SM-12502 on human platelets.
Köller M; Hilger RA; König W
Inflammation; 1996 Feb; 20(1):71-85. PubMed ID: 8926050
[TBL] [Abstract][Full Text] [Related]
59. Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets.
Nishihira J; Ishibashi T; Imai Y; Muramatsu T
Tohoku J Exp Med; 1985 Oct; 147(2):145-52. PubMed ID: 3001971
[TBL] [Abstract][Full Text] [Related]
60. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor.
Paulson SK; Wolf JL; Novotney-Barry A; Cox CP
Proc Soc Exp Biol Med; 1990 Nov; 195(2):247-54. PubMed ID: 2172997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
